Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Dividend investing allows individuals to generate steady cash flow from their investments. While extra cash is always welcome, some dividend stocks overdeliver and outperform the stock market.

Gilead is a top HIV treatment company ... which pays 3.2% per year in dividends. It's the most expensive stock on this list, trading at a forward P/E of 14. But even that is still incredibly ...

Investors in Gilead Sciences Inc (Symbol ... that would drive a total return (excluding dividends, if any) of 4.19% if the stock gets called away at the December 6th expiration (before broker ...

Merck, Gilead Sciences, and Novartis all offer generous dividend yields. These companies all have underrated growth prospects in the long run. At low valuations, they can be no-brainer buys for ...

Pharmaceutical titan Merck pays investors a dividend that yields 2.8% -- more ... Investors can secure an even higher-yielding stock with Gilead Sciences. It currently pays 3.6%, and this is ...